Instrumax CAD detectors empower peptide-based weight-loss drug R&D and quality control, driving innovation in the GLP-1 pharmaceutical industry.

In recent years, peptide-based weight-loss drugs, represented by GLP-1 receptor agonists, have rapidly become a focal point in the global pharmaceutical industry. From diabetes treatment to obesity management, and further expanding into new indications such as cardiovascular diseases, metabolic syndrome, and fatty liver disease, peptide drugs are demonstrating immense market potential. As innovative drug R&D and industrialization accelerate, the demand for high-performance analytical detection technologies continues to grow.

As a developer of domestic high-end charged aerosol detectors (CAD), Instrumax continues to advance the application of CAD technology in biopharmaceuticals, providing high-sensitivity and high-stability analytical solutions for peptide drug R&D, process development, and quality control.

In recent years, GLP-1 drugs have achieved rapid growth in the global market, with representative products including Semaglutide, Tirzepatide, and Liraglutide. These drugs not only demonstrate excellent performance in glycemic control but also show significant clinical value in weight management and cardiovascular protection, propelling the global peptide drug market into a new stage of development.

Meanwhile, an increasing number of long-acting GLP-1 agonists, multi-target agonists, and oral peptide drugs are entering the R&D pipeline, imposing higher requirements on the sensitivity, stability, and universality of analytical methods.

Peptide drugs typically exhibit complex molecular structures, diverse physicochemical properties, and a wide range of modification types. During R&D and production, comprehensive analysis of active ingredients, process-related impurities, degradation products, and excipients is required to ensure product quality, safety, and batch-to-batch consistency.

Typical analytical tasks include:

• Purity analysis of peptide raw materials;
• Detection of synthetic by-products and truncated peptides;
• Analysis of degradation products such as oxidation and deamidation;
• Analysis of excipients and stabilizers in formulations;
• Monitoring of process development;
• Stability studies;
• Quality control (QC) and release testing.

Instrumax CAD detectors operate on the charged aerosol detection principle, delivering stable responses for the vast majority of non-volatile compounds without dependence on specific ultraviolet absorption, serving as a critical universal detector for liquid chromatography.

In peptide drug analysis, CAD can be applied to:

• Purity assessment of peptide active pharmaceutical ingredients (APIs);
• Analysis of process-related impurities and by-products;
• Monitoring of synthesis processes;
• Stability studies and detection of degradation products;
• Analysis of pharmaceutical excipients;
• HPLC method development;
• Routine testing in QC laboratories.

For certain excipients, lipids, and polymers with weak or highly variable UV responses, CAD provides robust complementary detection capabilities. When used in conjunction with ultraviolet (UV) detectors and mass spectrometry (MS), it enhances the completeness of analytical results.

To extend in vivo half-life and improve patient compliance, many GLP-1 analogs employ strategies such as fatty acid conjugation, polymer modification, or sustained-release formulations. Concurrently, formulations extensively utilize excipients including polyethylene glycol (PEG) derivatives, surfactants, sugar-based stabilizers, and buffering salts.

These non-volatile excipients also require quantitative analysis during quality control. CAD detectors enable detection without reliance on chromophores and can be applied to:

• Analysis of PEG and PEG derivatives;
• Analysis of components related to fatty acid conjugation;
• Surfactant analysis;
• Analysis of sugar-based stabilizers;
• Monitoring of buffer salts and inorganic ions;
• Consistency evaluation of pharmaceutical excipients.

When coupled with liquid chromatography, the charged aerosol detector (CAD) enables researchers to gain a comprehensive understanding of pharmaceutical composition, providing reliable data support for process optimization and product release.

Centered on the R&D and industrialization of peptide therapeutics, Instrumax CAD detectors can be applied across multiple critical stages:

The CAD detector features universal response, high sensitivity, wide linear range, excellent repeatability, and compatibility with gradient elution, providing stable and reliable analytical support for peptide drug R&D and manufacturing.

With the rapid advancement of GLP-1 therapeutics and next-generation peptide therapies, high-performance analytical instrumentation will play an increasingly vital role in innovative drug discovery, process development, and quality control.

Instrumax will continue to advance CAD detector technology, expanding its applications in peptide drugs, nucleic acid therapeutics, biologics, natural products, and advanced formulations. We provide more efficient and reliable analytical solutions for research institutions, biotechnology companies, CROs/CDMOs, and pharmaceutical manufacturers, leveraging domestic innovative technology to support the high-quality development of China's biopharmaceutical industry.

Instrumax – The Eyes That Venture into the Unknown.